[4-(2,4-Dimethylphenyl)piperazin-1-yl](4-iodophenyl)methanone → (R)-[4-(2,4-dimethylphenyl)piperazin-1-yl][4-(4-methyl-1,1-dioxo-1lambda6-isothiazolidin-2-yl)phenyl]methanone
반응식
[CH3:1][C@H:2]1[CH2:6][S:5](=[O:8])(=[O:7])[NH:4][CH2:3]1.[CH3:9][C:10]1[CH:15]=[C:14]([CH3:16])[CH:13]=[CH:12][C:11]=1[N:17]1[CH2:22][CH2:21][N:20]([C:23]([C:25]2[CH:30]=[CH:29][C:28](I)=[CH:27][CH:26]=2)=[O:24])[CH2:19][CH2:18]1>>[CH3:9][C:10]1[CH:15]=[C:14]([CH3:16])[CH:13]=[CH:12][C:11]=1[N:17]1[CH2:18][CH2:19][N:20]([C:23]([C:25]2[CH:30]=[CH:29][C:28]([N:4]3[CH2:3][C@@H:2]([CH3:1])[CH2:6][S:5]3(=[O:8])=[O:7])=[CH:27][CH:26]=2)=[O:24])[CH2:21][CH2:22]1참가 물질
3
실험 절차
Using (R)-4-methylisothiazolidine 1,1-dioxide (203 mg) described in Preparation Example 7 and [4-(2,4-dimethylphenyl)piperazin-1-yl](4-iodophenyl)methanone (420 mg) described in Preparation Example 108 and by the reaction and treatment in the same manner as in Example 1, the title compound (39 mg) was obtained.
후처리
- custom